{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:27:55Z","timestamp":1791325675868,"version":"4.3.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,7]]},"DOI":"10.7759\/cureus.30021","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T11:14:19Z","timestamp":1665141259000},"source":"Crossref","is-referenced-by-count":7,"title":["Hemorrhagic Pericardial Effusion From Apixaban Use: Case Report and Literature Review"],"prefix":"10.7759","author":[{"given":"Syed Alishan","family":"Nasir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishan","family":"Babu Pokhrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyza","family":"Baig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","DOI":"10.1378\/chest.116.6.1564","article-title":"Bloody pericardial effusion in patients with cardiac tamponade: is the cause cancerous, tuberculous, or iatrogenic in the 1990s?","volume":"116","author":"Atar S","year":"1999","unstructured":"Atar S, Chiu J, Forrester JS, Siegel RJ. Bloody pericardial effusion in patients with cardiac tamponade: is the cause cancerous, tuberculous, or iatrogenic in the 1990s?. Chest. 1999, 116:1564-9.","journal-title":"Chest"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.14740\/cr902","article-title":"Spontaneous hemorrhagic pericardial and pleural effusion in a patient receiving apixaban","volume":"10","author":"Cinelli M","year":"2019","unstructured":"Cinelli M, Uddin A, Duka I, Soomro A, Tamburrino F, Ghavami F, Lafferty J. Spontaneous hemorrhagic pericardial and pleural effusion in a patient receiving apixaban. Cardiol Res. 2019, 10:249-52. 10.14740\/cr902","journal-title":"Cardiol Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.carrev.2019.04.002","article-title":"Hemorrhagic cardiac tamponade associated with apixaban: a case report and systematic review of literature","volume":"20","author":"Asad ZU","year":"2019","unstructured":"Asad ZU, Ijaz SH, Chaudhary AM, Khan SU, Pakala A. Hemorrhagic cardiac tamponade associated with apixaban: a case report and systematic review of literature. Cardiovasc Revasc Med. 2019, 20:15-20. 10.1016\/j.carrev.2019.04.002","journal-title":"Cardiovasc Revasc Med"},{"key":"ref4","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.01.2010.2606","article-title":"Cardiac tamponade secondary to haemopericardium in a patient on warfarin","volume":"2010","author":"Al-Jundi W","year":"2010","unstructured":"Al-Jundi W, Rubin N. Cardiac tamponade secondary to haemopericardium in a patient on warfarin. BMJ Case Rep. 2010, 2010:1-4.","journal-title":"BMJ Case Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000000775","article-title":"Cardiovascular side effects of tyrosine kinase inhibitor ibrutinib (imbruvica) and interaction with direct oral anticoagulant","volume":"25","author":"Khalid M","year":"2018","unstructured":"Khalid M, Khattak F, Ramu V. Cardiovascular side effects of tyrosine kinase inhibitor ibrutinib (imbruvica) and interaction with direct oral anticoagulant. Am J Ther. 2018, 25:e768-9. 10.1097\/MJT.0000000000000775","journal-title":"Am J Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly SJ","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al.. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009, 361:1139-51. 10.1056\/NEJMoa0905561","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct oral anticoagulant use: a practical guide to common clinical challenges","volume":"9","author":"Chen A","year":"2020","unstructured":"Chen A, Stecker E, Warden BA. Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc. 2020, 9:e017559. 10.1161\/JAHA.120.017559","journal-title":"J Am Heart Assoc"},{"key":"ref8","article-title":"Role of apixaban (Eliquis) in the treatment and prevention of thromboembolic disease","volume":"38","author":"Budovich A","year":"2013","unstructured":"Budovich A, Zargarova O, Nogid A. Role of apixaban (Eliquis) in the treatment and prevention of thromboembolic disease. P T. 2013, 38:206-31.","journal-title":"P T"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04369.x","article-title":"Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects","volume":"75","author":"Frost C","year":"2013","unstructured":"Frost C, Wang J, Nepal S, et al.. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol. 2013, 75:476-87. 10.1111\/j.1365-2125.2012.04369.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.carrev.2021.09.010","article-title":"Hemopericardium in the setting of direct oral anticoagulant use: an updated systematic review","volume":"39","author":"Sheikh AB","year":"2022","unstructured":"Sheikh AB, Shah I, Sagheer S, et al.. Hemopericardium in the setting of direct oral anticoagulant use: an updated systematic review. Cardiovasc Revasc Med. 2022, 39:73-83. 10.1016\/j.carrev.2021.09.010","journal-title":"Cardiovasc Revasc Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1602","article-title":"Spontaneous hemopericardium in a patient receiving apixaban therapy: first case report","volume":"35","author":"Sigawy C","year":"2015","unstructured":"Sigawy C, Apter S, Vine J, Grossman E. Spontaneous hemopericardium in a patient receiving apixaban therapy: first case report. Pharmacotherapy. 2015, 35:e115-7. 10.1002\/phar.1602","journal-title":"Pharmacotherapy"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4081\/cp.2019.1096","article-title":"Isolated hemopericardium after initiation of rivaroxaban: implications and potential mechanisms","volume":"9","author":"Mehta A","year":"2019","unstructured":"Mehta A, Burkland D, Mathuria N. Isolated hemopericardium after initiation of rivaroxaban: implications and potential mechanisms. Clin Pract. 2019, 9:1096. 10.4081\/cp.2019.1096","journal-title":"Clin Pract"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/1650716","article-title":"A rare case of spontaneous cardiac tamponade induced by concomitant use of rivaroxaban and amiodarone","volume":"2018","author":"Oladiran O","year":"2018","unstructured":"Oladiran O, Segal J, Nwosu I, Nazir S. A rare case of spontaneous cardiac tamponade induced by concomitant use of rivaroxaban and amiodarone. Case Rep Cardiol. 2018, 2018:1650716. 10.1155\/2018\/1650716","journal-title":"Case Rep Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd JC","year":"2015","unstructured":"Byrd JC, Furman RR, Coutre SE, et al.. Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015, 125:2497-506. 10.1182\/blood-2014-10-606038","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.07.287","article-title":"Risk of major bleeding with ibrutinib","volume":"18","author":"Mock J","year":"2018","unstructured":"Mock J, Kunk PR, Palkimas S, et al.. Risk of major bleeding with ibrutinib. Clin Lymphoma Myeloma Leuk. 2018, 18:755-61. 10.1016\/j.clml.2018.07.287","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcr\/ytx018","article-title":"Acute haemorrhagic tamponade in cancer patients receiving direct oral anticoagulant: case series","volume":"1","author":"Nassif T","year":"2017","unstructured":"Nassif T, Banchs J, Yusuf SW, Mouhayar E. Acute haemorrhagic tamponade in cancer patients receiving direct oral anticoagulant: case series. Eur Heart J Case Rep. 2017, 1:ytx018. 10.1093\/ehjcr\/ytx018","journal-title":"Eur Heart J Case Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccas.2022.04.015","article-title":"Left atrial appendage occlusion as\u00a0an\u00a0alternative to anticoagulants in\u00a0ibrutinib-induced hemorrhagic pericardial effusion","volume":"4","author":"Berti S","year":"2022","unstructured":"Berti S, De Caterina AR, Berger RD. Left atrial appendage occlusion as\u00a0an\u00a0alternative to anticoagulants in\u00a0ibrutinib-induced hemorrhagic pericardial effusion. JACC Case Rep. 2022, 4:755-7. 10.1016\/j.jaccas.2022.04.015","journal-title":"JACC Case Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-583294","article-title":"Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions","volume":"124","author":"Levade M","year":"2014","unstructured":"Levade M, David E, Garcia C. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood. 2014, 124:3991-5. 10.1182\/blood-2014-06-583294","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.143","article-title":"Cancer, inflammation, and therapy: effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents","volume":"96","author":"Harvey RD","year":"2014","unstructured":"Harvey RD, Morgan ET. Cancer, inflammation, and therapy: effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents. Clin Pharmacol Ther. 2014, 96:449-57. 10.1038\/clpt.2014.143","journal-title":"Clin Pharmacol Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7351","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014","volume":"33","author":"Lyman GH","year":"2015","unstructured":"Lyman GH, Bohlke K, Khorana AA, et al.. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol. 2015, 33:654-6. 10.1200\/JCO.2014.59.7351","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1R112","article-title":"Hemopericardium and cardiac tamponade associated with dabigatran use","volume":"46","author":"Dy EA","year":"2012","unstructured":"Dy EA, Shiltz DL. Hemopericardium and cardiac tamponade associated with dabigatran use. Ann Pharmacother. 2012, 46:e18. 10.1345\/aph.1R112","journal-title":"Ann Pharmacother"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.2012.01036.x","article-title":"Hemopericardium in a patient treated with dabigatran etexilate","volume":"32","author":"Barton CA","year":"2012","unstructured":"Barton CA, McMillian WD, Raza SS, Keller RE. Hemopericardium in a patient treated with dabigatran etexilate. Pharmacotherapy. 2012, 32:e103-7. 10.1002\/j.1875-9114.2012.01036.x","journal-title":"Pharmacotherapy"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2014.04.151","article-title":"Life-threatening haemorrhagic pericarditis associated with rivaroxaban","volume":"174","author":"Xu B","year":"2014","unstructured":"Xu B, MacIsaac A. Life-threatening haemorrhagic pericarditis associated with rivaroxaban. Int J Cardiol. 2014, 174:e75-6. 10.1016\/j.ijcard.2014.04.151","journal-title":"Int J Cardiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrtlng.2015.02.006","article-title":"A sanguineous pleuro pericardial effusion in a patient recently treated with Dabigatran","volume":"44","author":"Abdallah M","year":"2015","unstructured":"Abdallah M, Abdallah T, Abi Rafeh N, et al.. A sanguineous pleuro pericardial effusion in a patient recently treated with Dabigatran. Heart Lung. 2015, 44:209-11. 10.1016\/j.hrtlng.2015.02.006","journal-title":"Heart Lung"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.4070\/kcj.2016.46.1.99","article-title":"Hemopericardium and cardiac tamponade in a patient treated with dabigatran etexilate","volume":"46","author":"K\u0131z\u0131l\u0131rmak F","year":"2016","unstructured":"K\u0131z\u0131l\u0131rmak F, Gunes HM, Guler E, Demir GG, Karaca O, Canpolat HG. Hemopericardium and cardiac tamponade in a patient treated with dabigatran etexilate. Korean Circ J. 2016, 46:99-101. 10.4070\/kcj.2016.46.1.99","journal-title":"Korean Circ J"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1080\/08998280.2016.11929492","article-title":"Hemopericardium with tamponade following rivaroxaban administration and its attenuation by CYP3A4 inhibitors","volume":"29","author":"Menendez D","year":"2016","unstructured":"Menendez D, Michel J. Hemopericardium with tamponade following rivaroxaban administration and its attenuation by CYP3A4 inhibitors. Proc (Bayl Univ Med Cent). 2016, 29:414-5. 10.1080\/08998280.2016.11929492","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4691325","article-title":"Life-threatening hemopericardium associated with rivaroxaban","volume":"2017","author":"Basnet S","year":"2017","unstructured":"Basnet S, Tachamo N, Tharu B, Dhital R, Ghimire S, Poudel DR. Life-threatening hemopericardium associated with rivaroxaban. Case Rep Cardiol. 2017, 2017:4691325. 10.1155\/2017\/4691325","journal-title":"Case Rep Cardiol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008669","article-title":"Hemorrhagic pericardial effusion as the debut of acquired hemophilia in a chronic lymphocytic leukemia patient: a case report, and a review of acquired hemophilia A-related hematological malignancies","volume":"96","author":"Bastida JM","year":"2017","unstructured":"Bastida JM, Cano-Mozo MT, Lopez-Cadenas F, et al.. Hemorrhagic pericardial effusion as the debut of acquired hemophilia in a chronic lymphocytic leukemia patient: a case report, and a review of acquired hemophilia A-related hematological malignancies. Medicine (Baltimore). 2017, 96:e8669. 10.1097\/MD.0000000000008669","journal-title":"Medicine (Baltimore)"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.26420\/austincardiocardiovasccaserep.2017.1015","article-title":"Rivaroxaban and hemopericardium: is there an association?","volume":"2","author":"Gowani SA","year":"2017","unstructured":"Gowani SA, Omar S, Elmahdy HM, Kherada N, Sekhon A, Conde C, Santana O. Rivaroxaban and hemopericardium: is there an association?. Austin Cardio Cardiovas Case Rep. 2017, 2:1015. 10.26420\/austincardiocardiovasccaserep.2017.1015","journal-title":"Austin Cardio Cardiovas Case Rep"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.14503\/thij-16-6073","article-title":"Dabigatran-induced spontaneous hemopericardium and cardiac tamponade","volume":"44","author":"Jelani QJ","year":"2017","unstructured":"Jelani QJ, Gordon R, Schussheim AE. Dabigatran-induced spontaneous hemopericardium and cardiac tamponade. Tex Heart Inst J. 2017, 44:370-2. 10.14503\/thij-16-6073","journal-title":"Tex Heart Inst J"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.12793\/tcp.2017.25.3.138","article-title":"Hemorrhagic pericarditis associated with rivaroxaban in an atrial fibrillation patient with pacemaker","volume":"25","author":"Rhew SH","year":"2017","unstructured":"Rhew SH, Kim SS. Hemorrhagic pericarditis associated with rivaroxaban in an atrial fibrillation patient with pacemaker. Transl Clin Pharmacol. 2017, 25:138-40. 10.12793\/tcp.2017.25.3.138","journal-title":"Transl Clin Pharmacol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrcr.2017.11.015","article-title":"First reported case series in the United States of hemopericardium in patients on apixaban","volume":"4","author":"Sablani N","year":"2017","unstructured":"Sablani N, Garg J, Hasan B, Patel R, Martinez MW. First reported case series in the United States of hemopericardium in patients on apixaban. HeartRhythm Case Rep. 2017, 4:82-4. 10.1016\/j.hrcr.2017.11.015","journal-title":"HeartRhythm Case Rep"},{"key":"ref33","article-title":"Dabigatran-induced hemopericardium with tamponade","volume":"23","author":"Bitar ZI","year":"2020","unstructured":"Bitar ZI, Maadarani OS, Mohsen MJ, Zaalouk TM. Dabigatran-induced hemopericardium with tamponade. Crit Care Shock. 2020, 23:310-4.","journal-title":"Crit Care Shock"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijscr.2020.10.090","article-title":"Case report of simultaneous presentation of pulmonary embolism and pericardial effusion following an oncological esophagectomy","volume":"77","author":"Jou-Valencia D","year":"2020","unstructured":"Jou-Valencia D, Dijkstra FA. Case report of simultaneous presentation of pulmonary embolism and pericardial effusion following an oncological esophagectomy. Int J Surg Case Rep. 2020, 77:252-5. 10.1016\/j.ijscr.2020.10.090","journal-title":"Int J Surg Case Rep"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-238047","article-title":"Cardiac tamponade from anticoagulant-related spontaneous haemopericardium in a patient with ischaemic cardiomyopathy and heart failure","volume":"13","author":"Lefas A","year":"2020","unstructured":"Lefas A, Bodagh N, Pan J, Vazir A. Cardiac tamponade from anticoagulant-related spontaneous haemopericardium in a patient with ischaemic cardiomyopathy and heart failure. BMJ Case Rep. 2020, 13:e238047. 10.1136\/bcr-2020-238047","journal-title":"BMJ Case Rep"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcr\/ytaa482","article-title":"Hemopericardium with subsequent cardiac tamponade secondary to rivaroxaban treatment: a case report","volume":"5","author":"Shastri P","year":"2021","unstructured":"Shastri P, Bhuta S, Oostra C, Monroe T. Hemopericardium with subsequent cardiac tamponade secondary to rivaroxaban treatment: a case report. Eur Heart J Case Rep. 2021, 5:ytaa482. 10.1093\/ehjcr\/ytaa482","journal-title":"Eur Heart J Case Rep"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.13486","article-title":"A possible drug-drug interaction between eliquis and amiodarone resulting in hemopericardium","volume":"13","author":"Olagunju A","year":"2021","unstructured":"Olagunju A, Khatib M, Palermo-Alvarado F. A possible drug-drug interaction between eliquis and amiodarone resulting in hemopericardium. Cureus. 2021, 13:e13486. 10.7759\/cureus.13486","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/117647-hemorrhagic-pericardial-effusion-from-apixaban-use-case-report-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:50:37Z","timestamp":1707508237000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/117647-hemorrhagic-pericardial-effusion-from-apixaban-use-case-report-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,7]]},"references-count":37,"URL":"https:\/\/doi.org\/10.7759\/cureus.30021","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,7]]}}}